This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Baudry, P. J.
Right arrow Articles by Zhanel, G. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Baudry, P. J.
Right arrow Articles by Zhanel, G. G.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, May 2008, p. 1846-1849, Vol. 52, No. 5
0066-4804/08/$08.00+0     doi:10.1128/AAC.01176-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

Comparison of Antimicrobial Resistance Profiles among Extended-Spectrum-β-Lactamase-Producing and Acquired AmpC β-Lactamase-Producing Escherichia coli Isolates from Canadian Intensive Care Units{triangledown}

Patricia J. Baudry,1,2* Kim Nichol,2 Melanie DeCorby,1,2 Laura Mataseje,1,3 Michael R. Mulvey,1,3 Daryl J. Hoban,1,2 and George G. Zhanel1,2

Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, Winnipeg, R3A 1R9, Manitoba, Canada,1 Department of Clinical Microbiology, Health Sciences Centre, Winnipeg, R3A 1R9, Manitoba, Canada,2 National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, R3E 3R2, Manitoba, Canada3

Received 6 September 2007/ Returned for modification 10 November 2007/ Accepted 9 February 2008

Resistance profiles were compared among 18 extended-spectrum-β-lactamase-producing (ESBL) and 27 acquired AmpC β-lactamase-producing Escherichia coli isolates collected from Canadian intensive care units from 2005 to 2006. ESBL-producing E. coli isolates were more likely to be gentamicin resistant (P < 0.03), fluoroquinolone resistant (P < 0.0001), and multidrug resistant (P < 0.0001) than AmpC-producing E. coli isolates.

* Corresponding author. Mailing address: Health Sciences Centre, Department of Clinical Microbiology, MS673-820 Sherbrook St., Winnipeg, Manitoba, Canada, R3A 1R9. Phone: (204) 787-4684. Fax: (204) 787-4699. E-mail: trishbaudry{at}hotmail.com

{triangledown} Published ahead of print on 25 February 2008.

Antimicrobial Agents and Chemotherapy, May 2008, p. 1846-1849, Vol. 52, No. 5
0066-4804/08/$08.00+0     doi:10.1128/AAC.01176-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Zhanel, G. G., Baudry, P. J., Tailor, F., Cox, L., Hoban, D. J., Karlowsky, J. A. (2009). Determination of the pharmacodynamic activity of clinically achievable tigecycline serum concentrations against clinical isolates of Escherichia coli with extended-spectrum {beta}-lactamases, AmpC {beta}-lactamases and reduced susceptibility to carbapenems using an in vitro model. J Antimicrob Chemother 64: 824-828 [Abstract] [Full Text]  
  • Mataseje, L. F., Neumann, N., Crago, B., Baudry, P., Zhanel, G. G., Louie, M., Mulvey, M. R., and the ARO Water Study Group, (2009). Characterization of Cefoxitin-Resistant Escherichia coli Isolates from Recreational Beaches and Private Drinking Water in Canada between 2004 and 2006. Antimicrob. Agents Chemother. 53: 3126-3130 [Abstract] [Full Text]  


Copyright © 2010 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»